About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Depression Clinical Trials in Phoenix | 81 Studies

Clinical Trials DepressionPhoenix

Depression Clinical Trials in Phoenix

Find 81 clinical trials for depression near Phoenix, Arizona. Connect with research centers in your area.

All Depression trials nationwide All trials in Phoenix

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 1-20 of 81 trials

TerminatedA Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant TherapyThe purpose of this study is to assess the efficacy of Seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in…NCT04532749·Phoenix, Arizona and 79 others

Depression Trials in Other Cities

New York Los Angeles Chicago Houston Philadelphia San Antonio

Data from ClinicalTrials.govTerms

Active not recruiting"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.NCT06564818·Phoenix, Arizona and 44 others

CompletedEfficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive DisordersThe purpose of this study is to evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in patients with MDD with inadequate…NCT00326105·Phoenix, Arizona and 55 others

RecruitingA Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With DepressionIn this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression.NCT07610473·Phoenix, Arizona and 22 others

CompletedEfficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive DisordersThe purpose of this study is to demonstrate superior efficacy of Quetiapine fumarate sustained release (SEROQUEL) compared with placebo when used as a mono-therapy in the…NCT00326144·Phoenix, Arizona and 33 others

CompletedA Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 milligrams (mg) compared to placebo adjunctive to antidepressant therapy (ADT) in patients with…NCT02943577·Dothan, Alabama and 39 others

CompletedSafety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major…NCT01360866·Birmingham, Alabama and 141 others

CompletedStudy to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderThis is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA-335140 (formerly BTRX 335140) on symptoms of depression in participants…NCT06029426·Huntsville, Alabama and 63 others

CompletedA Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive DisorderThe primary purpose of this study is to evaluate the efficacy of SAGE-217 plus an ADT in the treatment of major depressive disorder (MDD) compared to placebo plus an ADT.NCT04476030·Dothan, Alabama and 50 others

CompletedComparison of Escitalopram Combination in Adult Patients With Major Depressive DisorderEscitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults.NCT00109044·Phoenix, Arizona and 17 others

CompletedA Study of Vilazodone in Pediatric Patients With Major Depressive DisorderThe purpose of this study is to evaluate the long-term safety and tolerability of vilazodone for the treatment of MDD in pediatric outpatients (7-17 years).NCT02436239·Birmingham, Alabama and 55 others

TerminatedStudy of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.NCT03668600·Birmingham, Alabama and 73 others

Not yet recruitingA Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive DisorderThis study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive…NCT07775300·Birmingham, Alabama and 168 others

CompletedStudy of Escitalopram in Adult Patients With Major Depressive DisorderEscitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults.NCT00108979·Phoenix, Arizona and 8 others

CompletedA Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)This study will evaluate the efficacy, safety and tolerability of agomelatine 25 mg or 50 mg per day and will compare agomelatine and paroxetine tolerability.NCT00463242·Phoenix, Arizona and 46 others

Not yet recruitingA Study to Evaluate BMS-986511 in Adults With Major Depressive DisorderA Study to Evaluate BMS-986511 in Adults with Major Depressive DisorderNCT07772531·Phoenix, Arizona and 26 others

CompletedA Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)This is a Phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with SAGE-217 in adult participants with MDD.NCT03864614·Dothan, Alabama and 51 others

CompletedA Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive DisorderThis is a Phase 2 clinical study evaluating the safety and effectiveness of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.NCT04479852·Phoenix, Arizona and 38 others

CompletedA Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive DisorderTo evaluate the efficacy and safety of AXS-05 relative to bupropion in subjects with treatment resistant major depressive disorder (MDD).NCT02741791·Phoenix, Arizona and 73 others

CompletedA Study to Explore the Efficacy of JNJ-67953964 in the Treatment of DepressionThe purpose of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo when administered as adjunctive treatment in participants with Major Depressive Disorder…NCT03559192·Tucson, Arizona and 52 others

Page 1 of 5Next

Other Conditions in Phoenix

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia